Logo do repositório
 
Publicação

Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA : a systematic review and a call for action

dc.contributor.authorRodrigues-Manica, Santiago
dc.contributor.authorSilva, Joana
dc.contributor.authorMachado, Ana Rita
dc.contributor.authorCoelho, Constança
dc.contributor.authorDuarte, Joana
dc.contributor.authorVieira De Sousa, Elsa Cristina
dc.contributor.authorTavares Costa, José
dc.contributor.authorPimentel Santos, Fernando M.
dc.date.accessioned2021-03-09T14:24:09Z
dc.date.available2021-03-09T14:24:09Z
dc.date.issued2020
dc.description© International League of Associations for Rheumatology (ILAR) 2020.pt_PT
dc.description.abstractThis paper is to assess the efficacy of different biologic DMARDs (bDMARDs) on several patient-reported outcomes (PROs) in randomized controlled trials (RCT) in axial spondyloarthritis (axSpA). A systematic literature review (SLR) was performed. MEDLINE (May 1, 2018) was used with the filters "published in the last 10 years" and "humans." The PICO criteria used were Patients: adults with radiographic axSpA (r-axSpA) or non-radiographic axSpA (nr-axSpA); Intervention: any bDMARD; Compararator: placebo (PBO)/any different drug; Outcome: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL), the EuroQol-5D (EQ-5D), the Short Form 36 Health Survey physical component summary (SF36-PCS), the Short Form 36 Health Survey mental component summary (SF36-MCS), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). After screening 84 initial references and manually selecting other 9, 24 publications, assessing TNF inhibitors (TNFi) or IL17A inhibitors (IL17Ai) were selected. Four RCTs quantified the minimal clinical important difference (MCID) between treatment arms. Most of the RCTs compared the mean difference of PROs between different timepoints. Overall, the treatment arm was superior to the comparator. PROs were often underreported or highly heterogeneously presented. MCID was seldom mentioned. There is a need to raise the standard of care on SpA by aiming at remission and PRO associated improvements. In order to achieve this goal, the target must be clearly defined, reported, and tested.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationClin Rheumatol. 2021 Jan;40(1):33-41pt_PT
dc.identifier.doi10.1007/s10067-020-05209-xpt_PT
dc.identifier.eissn1434-9949
dc.identifier.issn0770-3198
dc.identifier.urihttp://hdl.handle.net/10451/46745
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relation.publisherversionhttps://www.springer.com/journal/10067pt_PT
dc.subjectPROspt_PT
dc.subjectPatient-reported outcomespt_PT
dc.subjectRCTspt_PT
dc.subjectSpondyloarthritispt_PT
dc.subjectbDMARDspt_PT
dc.titleBiologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA : a systematic review and a call for actionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage41pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage33pt_PT
oaire.citation.titleClinical Rheumatologypt_PT
oaire.citation.volume40pt_PT
person.familyNameMachado
person.familyNameVieira de Sousa
person.givenNameAna Rita
person.givenNameElsa Cristina
person.identifier426629
person.identifier.ciencia-id1519-509A-8B89
person.identifier.orcid0000-0003-0600-876X
person.identifier.orcid0000-0002-7170-8802
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication47fa1e23-6318-4e58-a2b8-addce384ea94
relation.isAuthorOfPublication8b9873ad-2667-48e6-aece-a73dec6a8296
relation.isAuthorOfPublication.latestForDiscovery47fa1e23-6318-4e58-a2b8-addce384ea94

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Biologic_modifying.pdf
Tamanho:
371.49 KB
Formato:
Adobe Portable Document Format